Literature DB >> 26224626

Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Elia Mattarucchi1, Francesco Pallotti, Rosario Casalone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26224626     DOI： 10.1007/s40291-015-0152-5

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


× No keyword cloud information.
  7 in total

1.  Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Mireille Crampe; Stephen E Langabeer
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

2.  Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

3.  Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

Authors:  Elia Mattarucchi; Orietta Spinelli; Alessandro Rambaldi; Francesco Pasquali; Francesco Lo Curto; Leonardo Campiotti; Giovanni Porta
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

4.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Authors:  D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

5.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

Authors:  Jana Linhartova; Lenka Hovorkova; Simona Soverini; Adela Benesova; Monika Jaruskova; Hana Klamova; Jan Zuna; Katerina Machova Polakova
Journal:  Mol Cancer       Date:  2015-04-18       Impact factor: 27.401

Review 7.  Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.

Authors:  Francesca Pellicano; Leena Mukherjee; Tessa L Holyoake
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.